Redeye initiates coverage of Acarix

Redeye initiates coverage of Acarix. The company's significant potential hinges on its CADScor system’s invention of coronary artery disease (CAD) testing, plus an attractive razor/razorblade model under which high-margin (90%) disposable patches will generate the bulk of sales. While nearer-term upside is limited by the lack of reimbursement, the scope for the CADScor system to become a new standard supports the longer-term case.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.